You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Evobrutinib

Showing 1 - 18 of 18
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Healthy Trial in Nottingham (Ref (TF2), Evobrutinib MR-T1, Evobrutinib MR-T2)

Recruiting
  • Healthy
  • Ref (TF2)
  • +8 more
  • Nottingham, United Kingdom
    Quotient Clinical Ltd
Jul 11, 2022

Healthy Trial in Neu-Ulm (Evobrutinib, Carbamazepine)

Recruiting
  • Healthy
  • Neu-Ulm, Bavaria, Germany
    Nuvisan GmbH
Feb 9, 2022

Healthy Trial in Neu-Ulm (Evobrutinib, Digoxin, Metformin)

Completed
  • Healthy
  • Evobrutinib
  • +4 more
  • Neu-Ulm, Germany
    Nuvisan GmbH
Jan 10, 2022

Relapsing-remitting Multiple Sclerosis Trial in Rockland, Darmstadt (Evobrutinib, Avonex®, Avonex® matched Placebo)

Terminated
Has Results
  • Relapsing-remitting Multiple Sclerosis
  • Evobrutinib
  • +3 more
  • Rockland, Massachusetts
  • +1 more
Jul 13, 2021

Relapsing-remitting Multiple Sclerosis Trial in Rockland, Darmstadt (Evobrutinib, Avonex®, Avonex® matched Placebo)

Terminated
Has Results
  • Relapsing-remitting Multiple Sclerosis
  • Evobrutinib
  • +3 more
  • Rockland, Massachusetts
  • +1 more
Jul 13, 2021

Healthy Trial in Neu-Ulm (Midazolam, M2951)

Completed
  • Healthy
  • Neu-Ulm, Germany
    Nuvisan GmbH
Mar 22, 2021

Hepatic Impairment Trial in Kiel (M2951 (BTK inhibitor))

Completed
  • Hepatic Impairment
  • M2951 (BTK inhibitor)
  • Kiel, Germany
    CRS Clinical Research Services Kiel GmbH
Jul 9, 2021

Healthy Trial in Groningen (Evobrutinib)

Completed
  • Healthy
  • Evobrutinib
  • Groningen, Netherlands
    PRA Health Sciences
Jul 3, 2020

Healthy Trial in Neu-Ulm (Evobrutinib)

Completed
  • Healthy
  • Evobrutinib
  • Neu-Ulm, Germany
    Nuvisan GmbH
Jul 3, 2020

Healthy Trial in Neu-Ulm (Evobrutinib)

Completed
  • Healthy
  • Evobrutinib
  • Neu-Ulm, Germany
    Nuvisan GmbH
Jul 8, 2020

Relapsing-remitting Multiple Sclerosis Trial in Worldwide (Evobrutinib, Placebo, Tecfidera)

Active, not recruiting
Has Results
  • Relapsing-remitting Multiple Sclerosis
  • Evobrutinib
  • +2 more
  • Blagoevgrad, Bulgaria
  • +55 more
May 4, 2021

Relapsing Multiple Sclerosis Trial in Worldwide (Evobrutinib, Placebo (match to Teriflunomide), Teriflunomide)

Active, not recruiting
  • Relapsing Multiple Sclerosis
  • Evobrutinib
  • +3 more
  • Cullman, Alabama
  • +275 more
Nov 7, 2022

Relapsing Multiple Sclerosis Trial in Worldwide (Evobrutinib, Placebo (match to Teriflunomide), Teriflunomide)

Active, not recruiting
  • Relapsing Multiple Sclerosis
  • Evobrutinib
  • +3 more
  • Mobile, Alabama
  • +278 more
Nov 7, 2022

Rheumatoid Arthritis Trial in Worldwide (M2591 25 mg QD, M2951 75 mg QD, M2951 50 mg BID)

Completed
Has Results
  • Rheumatoid Arthritis
  • M2591 25 mg QD
  • +3 more
  • Phoenix, Arizona
  • +97 more
Sep 4, 2020

Renal Impairment Trial in Darmstadt (Evobrutinib)

Completed
  • Renal Impairment
  • Evobrutinib
  • Darmstadt, Germany
    Please Contact the Merck KGaA Communication Center
May 15, 2019

Systemic Lupus Erythematosus Trial in Worldwide (Placebo, M2951)

Terminated
Has Results
  • Systemic Lupus Erythematosus
  • Anniston, Alabama
  • +156 more
Mar 16, 2021

Rheumatoid Arthritis Trial in Billerica, Darmstadt (Placebo, M2951)

Completed
Has Results
  • Rheumatoid Arthritis
  • Billerica, Massachusetts
  • +1 more
Jun 18, 2018

Lupus Erythematosus, Systemic Trial in Bulgaria, United States (MSC2364447C, Placebo)

Completed
  • Lupus Erythematosus, Systemic
  • Anniston, Alabama
  • +12 more
Oct 6, 2017